Steven Snapinn - Concepedia

Author

Steven Snapinn

Also Known As

S M Snapinn, S SNAPINN, S Snapinn, S. SNAPINN, S. Snapinn, S.M. Snapinn, STEVEN M. SNAPINN, Steve Snapinn, Steven M Snapinn, Steven M. Snapinn

150

Publications

15.1K

Citations

H-Index

134

Concepts

All Affiliations

United States Military Academy Merck & Co., Inc., Rahway, NJ, USA (United States)Amgen (United States)Sahlgrenska University Hospital University of Michigan

About

Steven Snapinn is an author at United States Military Academy specializing in medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	10	11	282
2	Health Sciences	4	4	156
3	Business	2	2	305
4	Arts	1	1	14
5	Language Studies	1	1	16

Steven Snapinn

Publications

14.7K

Citations

H-Index

Page 1

	Year	Citations
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, New England Journal of Medicine	2001	7.4K
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lars Lindholm, Hans Ibsen, Björn Dahlöf, The Lancet HypertensionCardiovascular DiseaseHealth PolicyEndpoint ReductionRandomised Trial	2002	1.6K
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study William F. Keane, Barry M. Brenner, Dick de Zeeuw, Kidney International HemodialysisUrologyRenal DiseaseRenal FunctionMedicine	2003	542
Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes Christopher Heeschen, Christian W. Hamm, Ulrich Laufs, Circulation	2002	483
Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy Sverre E. Kjeldsen, Björn Dahlöf, Richard B. Devereux, JAMA	2002	442
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study Lars Lindholm, Hans Ibsen, Knut Borch‐Johnsen, Journal of Hypertension	2002	395
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol Peter M. Okin, Richard B. Devereux, Sverker Jern, Circulation	2003	256
Noninferiority trials Steven Snapinn Trials	2000	254
Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator Steven Snapinn, Qi Jiang, Boris Iglewicz The American Statistician Clinical EndpointPrognosisClinical Endpoint TrialsProspective Cohort StudyExtended Kaplan-meier Estimator	2005	234
Intracoronary Thrombus and Platelet Glycoprotein IIb/IIIa Receptor Blockade With Tirofiban in Unstable Angina or Non–Q-Wave Myocardial Infarction Xue-Qiao Zhao, Pierre Théroux, Steven Snapinn, Circulation	1999	217

Page 1